Uro-Oncology Asia 2019 | MIMS Malaysia

Research sheds light on PARP inhibitor use in mCRPC

Jackey Suen, 20190306023055

The future of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the treatment of metastatic castration-resistant prostate cancer (mCRPC) is promising in light of encouraging results from recent clinical studies.

Immune-checkpoint inhibitors changing the landscape of bladder cancer management

Dr. Joseph Delano Fule Robles, 20190304042018

Since the approval of immune checkpoint inhibitors (ICIs) as standard of care in the second-line setting for metastatic urothelial carcinoma, new approaches on how clinicians manage this condition are emerging.

Robot-assisted radical cystectomy comparable to open cystectomy for urologic cancers

Dr. Joseph Delano Fule Robles, 20190222084223

Studies have demonstrated that robot-assisted radical cystectomy (RARC) is as effective and has a cost advantage compared with open cystectomy for the management of urologic cancers.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 20190130073512

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.